Skip to main content
SpringerLink
Log in

Ombitasvir/paritaprevir/ritonavir

Hepatotoxicity: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Janczewska E, et al. Efcacy of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin in patients with HCV genotype 1 and 4 infection-fnal data from the real-world AMBer study. Clinical and Experimental Hepatology 2: 76, No. 2, Jan 2016 [abstract] - Poland

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ombitasvir/paritaprevir/ritonavir. Reactions Weekly 1694, 341 (2018). https://doi.org/10.1007/s40278-018-43742-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-43742-2

Search

Navigation